benzyl 4-(4H-1,2,4-triazol-3-yl)piperidine-1-carboxylate | 893424-27-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 4-(4H-1,2,4-triazol-3-yl)piperidine-1-carboxylate
• 英文别名: benzyl 4-(1H-1,2,4-triazol-3-yl)piperidine-1-carboxylate；benzyl 4-(1H-1,2,4-triazol-5-yl)piperidine-1-carboxylate
• CAS: 893424-27-6
• 化学式: C₁₅H₁₈N₄O₂
• 分子量: 286.334
• InChiKey: ACNBOWAEOFAGKJ-UHFFFAOYSA-N

物化性质

• 沸点：
  500.9±60.0 °C(Predicted)
• 密度：
  1.273±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  71.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl 4-(4H-1,2,4-triazol-3-yl)piperidine-1-carboxylate 在 钯 氢气 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以to give 21-1 as a solid的产率得到4-(4H-1,2,4-triazol-3-yl)piperidine
  参考文献：
  名称：

  Inhibitors of akt activtiy

  摘要：

  本发明提供了替代萘啶化合物，其抑制Akt活性。具体来说，所披露的化合物选择性地抑制一种或两种Akt亚型。本发明还提供了包含这种抑制剂化合物的组合物以及通过向需要癌症治疗的患者施用该化合物来抑制Akt活性的方法。

  公开号：

  US08008317B2
• 作为产物：
  描述：

  甲酰肼 、 1-N-Cbz-4-氰基哌啶 在 sodium methylate 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 96.5h， 生成 benzyl 4-(4H-1,2,4-triazol-3-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  WO2006/135627

  摘要：

  公开号：

文献信息

• [EN] INHIBITORS OF AKT ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ D'AKT
  申请人：MERCK SHARP & DOHME

  公开号：WO2010088177A1

  公开（公告）日：2010-08-05

  The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了抑制Akt活性的化合物。具体而言，所披露的化合物选择性地抑制一种或两种Akt同工酶。该发明还提供了包含这些抑制性化合物的组合物以及通过向需要癌症治疗的患者施用该化合物来抑制Akt活性的方法。
• INHIBITORS OF AKT ACTIVITY
  申请人：Layton Mark E.

  公开号：US20100022573A1

  公开（公告）日：2010-01-28

  The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了替代萘啶化合物，其抑制Akt活性。具体而言，所披露的化合物选择性地抑制一种或两种Akt亚型。本发明还提供了包含这种抑制剂化合物的组合物以及通过向需要治疗癌症的患者施用该化合物来抑制Akt活性的方法。
• Inhibitors of Akt Activity
  申请人：Arruda Jeannie M.

  公开号：US20080287457A1

  公开（公告）日：2008-11-20

  The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

  本发明涉及含有取代萘啶的化合物，其抑制Akt蛋白激酶的活性。本发明还涉及含有本发明化合物的化疗组合物以及治疗癌症的方法，包括给予本发明化合物的治疗方法。这些取代萘啶与PCT出版物WO2003/086394中报告的其他萘啶相比具有意外的优点，这些意外的优点可能包括增强的细胞效力/溶解度、更大的选择性、增强的药代动力学性质、缺乏非靶标活性等。
• Inhibitors of AKT Activity
  申请人：Armstrong Donna J.

  公开号：US20110288090A1

  公开（公告）日：2011-11-24

  The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了抑制Akt活性的化合物。特别地，所披露的化合物选择性地抑制一种或两种Akt同工型。本发明还提供了包含这种抑制剂化合物的组合物以及通过向需要癌症治疗的患者施用该化合物来抑制Akt活性的方法。
• Inhibitors of Akt activity
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07910561B2

  公开（公告）日：2011-03-22

  The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

  本发明涉及含有取代萘啶的化合物，其能够抑制Akt酶的活性，Akt酶是一种丝氨酸/苏氨酸蛋白激酶。本发明还涉及包含本发明化合物的化疗组合物以及治疗癌症的方法，包括给予本发明化合物的治疗。与PCT出版物WO2003/086394中报道的其他萘啶相比，这些取代萘啶具有意外的优势特性，这些意外的优势特性可能包括增加的细胞效力/溶解度，更强的选择性，增强的药代动力学特性，缺乏非特异性作用等。